Bui KT,Willson ML,Goel S,Beith J,Goodwin A .2020 .Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst. Rev., 3(3) : CD013538.
Cheng Y,Li N,Eapen A,Parajuli R,Mehta R .2019 .Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in PlatinumExposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. Case Rep. Oncol., 12(2) : 494-499.
Giuliano M,Schettini F,Rognoni C,Milani M,Jerusalem G,Bachelot T,Generali D .2019 .Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2- negative, metastatic breast cancer: A systematic review and network meta-analysis. Lancet Oncol., 20(10) : 1360-1369.
Goto R,Uda A,Hiroi S,Iwasaki K,Takashima K,Kurebayashi J .2017 .Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations. J. Med, 20(11) : 1163-1169.
Han W and Youn HJ .2019 .Clinical studies investigating the use of leuprorelin in breast cancer patients from Asia. Asian Pac. J. Cancer Prev, 20(5) : 1475-1479.
Hannah-Shmouni F,Moraitis AG,Romero VV,Faucz FR,Mastroyannis SA,Berthon A,Stratakis CA .2018 .Successful treatment of estrogen excess in primary bilateral macronodular adrenocortical hyperplasia with leuprolide acetate. Horm. Metab. Res., 50(2) : 124-132.
Hansra D,Jackson S,Sequeira J,Vazirani R,Alvarez R .2020 .Male patient with metastatic stage IV breast cancer achieves complete remission on second line abemaciclib, fulvestrant and leuprolide: A case report. Mol. Clin. Oncol., 12(2) : 120-125.
Kendzierski DC,Schneider BP,Kiel PJ .2018 .Efficacy of different leuprolide administration schedules in premenopausal breast cancer: A retrospective review. Clin. Breast Cancer, 18(5) : e939-e942.
Kojima N,Yamasaki Y,Koh H,Miyashita M,Morita H M .2018 .Long-acting luteinizing hormone-releasing hormone agonist for ovarian hyperstimulation induced by tamoxifen for breast cancer. Case Rep. Obstet. Gynecol., 4931852 : .
Kurebayashi J,Toyama T,Sumino S,Miyajima E,Fujimoto T .2017 .Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: A phase III, randomized, open-label, parallel-group comparative study. Breast Cancer, 24(1) : 161-170.
Lee J,Im SA,Kim GM,Jung KH,Kang SY,Park IH,Park YH .2021 .Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: Subgroup analyses of KCSG-BR15-10 (YoungPEARL). Cancer Res. Treat., 53(3) : 695-702.
Li T,Mello-Thoms C,Brennan PC C .2016 .Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res. Treat., 159(3) : 395-406.
Mistry R,May JR,Suri G,Young K,Brixner D,Oderda G .2018 .Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: A U.S. payer perspective. J. Manag. Care Spec Pharm., 24(6) : 514-523.
Ozaki Y,Tanabe Y,Tamura N,Ogura T,Kondoh C,Miura Y,Takano T Y .2018 .Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: A retrospective single-institution study. Breast Cancer, 25(3) : 343-349.
Park YH,Kim TY,Kim GM,Kang SY,Park IH,Kim JH,Im SA .2019 .Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial. , 20(12) : 1750-1759.
Sansone P,Ceccarelli C,Berishaj M,Chang Q,Rajasekhar VK,Perna F,Bromberg J F .2016 .Selfrenewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat. Commun, 7 : 10442.
Strini V,Piazzetta N,Gallo A,Schiavolin R .2020 .Barthel Index: creation and validation of two cut-offs using the BRASS Index. , 91 : 19-26.
Tanios G,Mungo NA,Kapila A,Bajaj K A .2017 .Pituitary apoplexy: A rare complication of leuprolide therapy in prostate cancer treatment. BMJ. Case Rep., bcr2016218514., : .
Taylor-Stokes G,Mitra D,Waller J,Gibson K,Milligan G,Iyer S G .2019 .Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. Breast, 43 : 22-27.
von Hippel C,Rosenberg SM,Austin SB,SprunckHarrild K,Ruddy KJ,Schapira L,Partridge AH .2019 .Identifying distinct trajectories of change in young breast cancer survivors sexual functioning. Psychooncology, 28(5) : 1033-1040.
Waller J,Mitra D,Mycock K,Taylor-Stokes G,Milligan G,Zhan L,Iyer S L .2019 .Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in Argentina: The IRIS study. J. Glob Oncol., 5 : Jgo1800239.
Zhang P,Li CZ,Jiao GM,Zhang JJ,Zhao HP,Yan F,Jia SF,Hu BS,Wu CT .2017 .Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials. Eur. J. Surg, 43(7) : 1161-1172.
Zhu J,Davis CT,Silberman S,Spector N,Zhang T .2016 .A role for the androgen receptor in the treatment of male breast cancer. Crit. Rev. Oncol. Hematol, 98 : 358-363.